| Document |
Document Title |
|
WO/2013/092753A1 |
The present invention encompasses compounds having general formula (I) able to inhibit the lactate production (lactic acid) involved in the angiogenesis of tumoral tissues, in the glycolytic metabolic process of tumoral cells, of immune ...
|
|
WO/2013/093849A1 |
The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the desc...
|
|
WO/2013/088404A1 |
The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malari...
|
|
WO/2013/087965A1 |
The invention relates to scorpion‑tail-like macrocyclic compounds and to the use thereof as antiparasitic agents. The present invention relates to scorpion‑tail-like macrocyclic compounds that are so named owing to the particular for...
|
|
WO/2013/083991A1 |
The invention provides compounds which inhibit N-myristoyltransferase and are selective for protozoal N-myristoyltransferase and, consequently suitable to treat microbial infections, including viral and fungal infections, and protozoan i...
|
|
WO/2013/079407A1 |
The present invention relates to the use of compounds of formula (I), wherein the variables are as defined in the description, in the free form or in salt form, for the manufacture of a medicament for controlling ectoparasites on a warm-...
|
|
WO/2013/081783A1 |
Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein (1), Q, A, R1, R2, R3 and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula (1) and methods for treating hel...
|
|
WO/2013/082373A1 |
This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and pre...
|
|
WO/2013/076231A1 |
The invention relates to the use of fluopyram for controlling endoparasites in humans and animals, to drugs containing fluopyram, to a method for producing drugs and to a method for treating humans and animals to control endoparasites, e...
|
|
WO/2013/076230A1 |
The invention relates to known and novel aryl and hetaryl carboxamides of formula (I), to the use thereof as drugs for fighting endoparasites in animals or humans, and to parasiticidal agents, in particular endoparasiticides, that contai...
|
|
WO/2013/077186A1 |
The purpose of the present invention is to provide: an immunomodulator which can be used as an immunostimulator useful for maintaining, improving or suppressing an immune function in association with CD300a activity signaling, or as an i...
|
|
WO/2013/075596A1 |
The present invention relates to the synthesis and use of a pentabasic dihydrogen heterocyclic ketone derivative of general formula (I) used as a DHODH inhibitor for Plasmodium falciparum, and the compound related to the present inventio...
|
|
WO/2013/074930A1 |
Methods are provided to inhibit proliferation of Leishmania parasites, and in particular Leishmania donovani with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can...
|
|
WO/2013/074892A1 |
This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds in combination with substituted imidazole compounds. This invention also provides for an improved methods for eradicating, con...
|
|
WO/2013/071365A1 |
A method for the treatment or prophylaxis of a subject infected with or who has or had exposure to a member of Phylum Apicomplexa, said method comprising administering to said subject an effective amount of griseofulvin or N-methyl proto...
|
|
WO/2013/071715A1 |
The present invention includes histone deacetylase inhibitors represented by formula I, wherein R1 to R8 are defined in the specification. The present invention also comprises s the synthetic method of the compounds, and the use of the c...
|
|
WO/2013/069771A1 |
A compound represented by formula (I) has an excellent noxious organism control activity. [R1 represents a C1-8 alkyl group or the like; W represents a halogen atom or the like; n represents an integer of 0 to 4; A represents a bicycic t...
|
|
WO/2013/068551A1 |
The present invention relates to novel compounds (I) containing two disubstituted triazine rings covalently linked by an organic linker, thereby creating dimers. These compounds show activity against the causative infective agents of inf...
|
|
WO/2013/063673A1 |
The present invention relates to the preparation of a pharmaceutical composition containing a pharmacologically active quantity of a synthetic substance created in a laboratory from a modified alkaloid from a plant species, or synthetica...
|
|
WO/2013/065725A1 |
The present invention relates to a phthalamide derivative represented by general formula (I) or a salt thereof. [In the formula, X1 represents a halogen atom or the like; X2 represents a halogen atom or the like; m represents 0, 1, 2 or ...
|
|
WO/2013/066643A1 |
Compositions and Methods are described in which Albendazole sulfone binds to Wolbachia FtsZ providing anti filarial activity.
|
|
WO/2013/064521A1 |
A compound of formula (I) wherein R1 to R4 are, for example, each hydrogen, R5 is pyridyl, which has two or more substituents selected, for example, from halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1 -C4-alkoxy, C1 -C4-haloalkoxy, and cyano;...
|
|
WO/2013/064520A1 |
A compound of formula (I) wherein R1 to R4 are, for example, each hydrogen, R5 is, for example, a substituted phenol; R6 is, for example, hydrogen; R7 is, for example, hydrogen, cyano, hydroxyl, formyl, C1 -C4-alkyl, C1 -C4-alkoxy, C2-C4...
|
|
WO/2013/061977A1 |
The present invention pertains to the compound represented by formula (I) (in the formula: X1, X2, X3, X4, X5, R5, R6, R7, R8, n, p, q, ring A, and ring B have the same meaning as the definitions described in the description) or a pharma...
|
|
WO/2013/059898A1 |
One of the greatest difficulties encountered in the treatment of Chagas disease by chemotherapy is the natural resistance of T. cruzi to the pharmaceuticals available, and also the fact that parasites that are resistant to a certain comp...
|
|
WO/2013/061455A1 |
The present invention relates to: a resveratrol polymerization compound represented by formula (1) (wherein R1 and R2 independently represent -OH or a group represented by formula (i), wherein R1 and R2 are different from each other) or ...
|
|
WO/2013/063271A1 |
An all-natural herbal composition and methods of preparing the same are provided. The novel Artemisinin Combination Therapy (ACT) consists of artemisinin and its derivatives and berberine, the two active substances mixed with various sel...
|
|
WO/2013/056730A1 |
It is disclosed a composition of one or more active compounds belonging to the group of neonicotinoids suitable to be administered to humans and used to kill free-living blood feeding ectoparasites including ectoparasitic arthropods. The...
|
|
WO/2013/057222A2 |
The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of â€...
|
|
WO/2013/054148A1 |
The present invention relates to the use of bismuth ions, particularly the Bi+3 ion, in the manufacture of a medicament for the prevention and/or treatment of the haemolytic uremic syndrome. Furthermore, the invention relates to the use ...
|
|
WO/2013/027196A9 |
In one aspect, the invention relates to novel substituted 2-alkyl-1-oxo-N-phenyl-3-heteroaryl-,2,3,4-tetrahydroisoquin
oline-4-carboxamides; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds...
|
|
WO/2013/055920A1 |
The invention relates to compositions for treating parasitic worm infections in a mammal. The composition includes an amount of intracellular components of lysed, beneficial, soil-inhabiting yeast cells sufficient to treat parasitic worm...
|
|
WO/2013/052012A1 |
The disclosure provides cationic peptidopolysaccharides of Formula I: which has a bacterial peptidoglycan-mimetic structure, and shows outstanding broad spectrum activities against clinically significant bacteria and fungi. The structura...
|
|
WO/2013/045734A1 |
The invention relates to compounds with the general formula (I), to a method for synthesising same and to compositions that include said compounds, intended for the treatment of diseases caused by parasites of the Leishmania genus.
|
|
WO/2013/047144A1 |
A cyclic amine compound represented by formula (I) or a salt thereof. In the formula, Cy1 represents a phenyl group or the like; each R10 is a substituent of Cy1 and independently represents an unsubstituted or substituted C1-6 alkyl gro...
|
|
WO/2013/045730A1 |
Use of oxoisoaporphines in combating leishmaniasis. Data are provided on the in-vitro activity of compounds with an oxoisoaporphine structure as compared with species of the genus Leishmania: L. amazonensis, L. infantum, L. braziliensis ...
|
|
WO/2013/044116A1 |
Antimicrobial compositions including a cell penetrating peptide (CPP) having the amino acid sequence Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly- Pro-Arg-Gly-Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Arg (SEQ ID NO: 1) or variant thereof are disclosed...
|
|
WO/2013/043961A1 |
The present invention relates to compounds useful as inhibitors of choline kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of v...
|
|
WO/2013/041480A1 |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other d...
|
|
WO/2013/040750A1 |
Provided is a method for synthesizing β-Artemether. The method uses dihydroartemisinin as a raw material, which has an etherifying reaction with trimethyl orthoformate in an organic solvent in the presence of catalyst, to give β-Arteme...
|
|
WO/2013/043064A1 |
A two part container (10) for veterinary products enabling two different but mixable liquid formulations to be stored separately in one pack having dual chambers (11) and (12) and mixed prior to application. One of the liquid formulation...
|
|
WO/2013/039948A1 |
This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or mo...
|
|
WO/2013/034756A1 |
The present invention relates to a compound of formula (I), wherein R1 and R2 are independently selected from (a) C1 to C6 alkyl; C2 to C6 alkenyl; C2 to C6 alkynyl; substituted or unsubstituted heterocycloalkyl or cycloalkyl, substituen...
|
|
WO/2013/030768A1 |
Methods and compositions for the treatment of pediculosis comprising: between 1 and 20% (w/w) isopropyl myristate; between 1 and 20% (w/w) silicone oil; and at least 20% (w/w) water. Methods and compositions for dissolving nit glue compr...
|
|
WO/2013/031239A1 |
[Problem] The present invention addresses the problem of providing an anti-trypanosomal drug having a novel skeleton, in order to solve issues that occur with conventional technologies. [Solution] The present invention is based on the di...
|
|
WO/2013/026117A1 |
In general, the present invention relates to veterinary compositions that can be used for treating parasitic diseases in animals, particularly dairy cattle, comprising avermectins and specific excipients acceptable for veterinary purpose...
|
|
WO/2013/024004A1 |
The present invention relates to N-thio-anthranilamide compounds of formula (I) and the stereoisomers, salts, tautomers and N-oxides thereof and to compositions comprising the same. The invention also relates to the use of the N-thio-ant...
|
|
WO/2013/023540A1 |
Disclosed are a compound of Formula (I) and use thereof in control of chicken coccidiosis. The compound of Formula (I) is prepared from a compound of Formula (II) or a phenolic sodium salt thereof and a compound of Formula (III) through ...
|
|
WO/2013/021363A1 |
The invention relates to antibacterial compounds of formula (I), wherein R1 is H, halogen, (C1-C3)alkyl or (C1-C3)alkoxy; R2 is H, halogen, (C1-C3)alkyl, (C1-C3)alkoxy or pyrrolidin-l-yl; R3 is H, halogen, (C1-C3)alkyl, (C1-C3)alkoxy, vi...
|
|
WO/2013/018069A1 |
The present invention relates to a combination comprising a compound of the formula I and one or more other antimalarial agent, especially for use as a medicament to treat or prevent malaria infections or to treat or prevent other protoz...
|
